Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 68001-0485
Overview:
NDC 68001-0485 corresponds to Tafasitamab (marketed as Monjuvi), a monoclonal antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide. Since its FDA approval in August 2020, demand has grown within niche hematologic oncology indications. Its market dynamics depend on competition, brand positioning, and regulatory factors.
Current Market Landscape
Therapeutic Area:
- Primarily used for DLBCL patients who do not respond to first-line therapies.
- Part of the broader B-cell lymphoma treatment segment, which includes CAR T-cell therapies such as axicabtagene ciloleucel and tisagenlecleucel, as well as other monoclonal antibodies like rituximab and polatuzumab.
Key Competitors:
- CAR T-cell therapies (e.g., Yescarta, Kymriah) with high efficacy but significant costs.
- Other monoclonal antibody therapies (e.g., Rituxan/MabThera) with more extensive market penetration.
- Emerging therapies targeting similar pathways or with novel mechanisms.
Market Size (2023):
- Estimated global sales of Monjuvi reached approximately $200 million.
- The US accounts for over 80% of sales, driven by FDA approval and reimbursement dynamics.
Market Drivers:
- Growing incidence of lymphoma globally—estimated at approximately 80,000 new cases annually in the US.
- Increasing adoption in relapsed/refractory settings due to favorable safety profile relative to CAR T-cells.
- Expanding label indications and combination therapies.
Market Challenges:
- Competition from highly effective CAR T-cell therapies, which have shown complete response rates upwards of 50%.
- High treatment costs (~$370,000 per patient for CAR T therapies), leading to payer restrictions.
- Off-label use and reimbursement hurdles.
Price Projections (2024-2028)
| Year |
Estimated US Wholesale Acquisition Cost (WAC) per 200mg vial |
Projected US Sales |
Pricing Factors |
Notes |
| 2024 |
~$7,000 per vial |
$250 million |
Industry inflation, payer negotiations, uptake rates |
Slight price erosion expected due to biosimilar pressures and payer controls |
| 2025 |
~$6,900 per vial |
$275 million |
Increased adoption, expanded indications |
Growth driven by increasing utilization in combination therapy |
| 2026 |
~$6,800 per vial |
$300 million |
Possible biosimilar entry, pricing negotiations |
Biosimilar landscape likely to influence pricing stability |
| 2027 |
~$6,700 per vial |
$330 million |
Market saturation, expanded access |
Potential pipeline developments or combination uses may boost sales |
| 2028 |
~$6,600 per vial |
$350 million |
Competitive pressures, higher market penetration |
Ongoing patent protections expected until 2032, delaying biosimilar entries |
Assumptions:
- No significant regulatory or clinical setbacks.
- Continued prevalence of relapsed/refractory DLBCL remains stable or increases slightly.
- Biosimilar competition emerges around 2025-2026, leading to price erosion.
Regulatory and Policy Impact
- Patent Protections: Patents extend until approximately 2032, limiting biosimilar entry.
- Healthcare Policies: Payer cost-containment measures may pressure price reductions.
- Reimbursement Trends: Favorable coverage for monoclonal antibodies in oncology support revenue growth.
- Biosimilar Development: Several biosimilars are under development, targeting similar indications; entry is likely around 2025-2026.
Market Outlook Summary
- Short-Term (2024-2025): Slow growth in sales (~10-15%), minor price declines due to biosimilar threat.
- Mid-Term (2026-2028): Stronger growth (10-15% annually) driven by expanded indication and combination use.
- Long-Term: Market stabilization with biosimilar competition likely capping price but maintaining market share.
Key Takeaways
- Demand is driven by relapsed/refractory DLBCL cases and limited first-line alternatives.
- Pricing is projected to decline moderately over time, influenced by biosimilar competition and payer pressures.
- Sales growth depends on clinical adoption, regulatory environment, and competition from innovative therapies like CAR T-cells.
- Market dynamics are sensitive to shifts in treatment paradigms, reimbursement policies, and biosimilar approvals.
- Potential exists for incremental growth through combination therapies and expanded indications, pending regulatory approvals.
FAQs
1. How does the presence of biosimilars affect the price of NDC 68001-0485?
Biosimilar entry typically leads to price reductions of 20-30% within 1-2 years of market launch, depending on market share and competition.
2. What are the main differentiators of Monjuvi compared to CAR T therapies?
Monjuvi offers an outpatient administration, lower toxicity profile, and lower upfront costs, making it an alternative for patients ineligible for CAR T treatment.
3. Are there upcoming regulatory changes that could impact the market?
Potential inclusion of Monjuvi in broader lymphoma treatment guidelines or expanded indications could increase sales; conversely, biosimilar approval pathways may accelerate price erosion.
4. How does market penetration vary across regions?
The US dominates sales due to early approval and reimbursement policies. European and Asian markets are expected to grow steadily but face different regulatory timelines and pricing controls.
5. What clinical trials could influence future pricing or market share?
Trials exploring monotherapy efficacy, combination with other agents, or first-line use could shift market dynamics, especially if they demonstrate superior outcomes or safety profiles.
References
[1] IQVIA. "Pharma Sales Data, 2023."
[2] FDA. "Monjuvi (Tafasitamab) Approval Notification, 2020."
[3] EvaluatePharma. "Oncology Market Forecasts, 2023."
[4] Centers for Disease Control and Prevention. "Lymphoma Incidence Data," 2022.
[5] Company SEC Filings and Investor Presentations, 2023.
